Pyrazolopyrimidine Compounds Selective IFNα Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as allergic rhinitis and asthma, and infectious diseases lack effective inducers of human interferon, particularly those that selectively induce IFNα over TNFα, and existing vaccine adjuvants are not optimal for modulating immune responses.
Innovation Solution
Development of specific compounds of formula (I) and their salts, which act as potent immunomodulators by inducing human interferon, particularly IFNα, and can be used in pharmaceutical compositions for treating allergic diseases, infectious diseases, and as vaccine adjuvants, with a desirable developability profile and selectivity for IFNα over TNFα.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for allergic diseases and infectious diseases are used, then current standard therapy is provided, but effective induction of human interferon (particularly IFNα) is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of imidazoquinoline compounds (changing molecular parameters) to create compounds with enhanced ability to induce IFNα. The structural modifications include varying substituents at specific positions on the imidazoquinoline core, which changes the biological activity parameters of the compounds to achieve selective IFNα induction.
Solution Approach 2:
The patent creates new compounds that copy and optimize the beneficial effects of natural TLR7 ligands. By studying the structure-activity relationships of natural ligands and creating synthetic analogs, the patent produces compounds that replicate and enhance the interferon-inducing capability while improving selectivity for IFNα over other cytokines.
2Adaptability or versatility
If compounds that induce both IFNα and TNFα are used, then immune response is stimulated, but selective induction of IFNα over TNFα is not achieved
Solution Approach 1:
The patent applies local quality by making specific localized modifications to the imidazoquinoline structure at particular positions (such as substituents at positions 1, 2, and 7) to achieve selective IFNα induction. These localized structural changes at specific sites on the molecule confer the desired selectivity without requiring complete redesign of the entire molecular structure.
3Reliability
If conventional vaccine adjuvants are used, then immune response is enhanced, but optimal modulation of immune responses is not achieved
Solution Approach 1:
The patent applies universality by designing compounds that can serve multiple functions: they act as TLR7 agonists to induce interferons, serve as vaccine adjuvants to enhance immune responses, and potentially treat both allergic diseases and infectious diseases. This multi-functionality allows a single compound class to address multiple therapeutic needs.
Data Source
AI summary
Compounds of formula (I) and salts thereof:wherein R1 is n-C1-6alkyl or C1-2alkoxyC1-2alkyl-, R2 is halo, OH or C1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.